[1]
N. Ashoush, “REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO-TRANSPORTER-2 (SGLT-2)”, Asian J Pharm Clin Res, vol. 10, no. 7, pp. 50–56, Jul. 2017.